Evotec has a long history of contributing to the oncology field through partners, achieving numerous oncology milestones including multiple PDCs, 14 clinical drugs and 1 marketed product.
Our dedicated oncology team assists pharmaceutical, biotech, not-for-profit and academic organisations in their drug discovery research activities offering a comprehensive panel of activities from target identification to IND through a highly sophisticated and integrated drug discovery platform.
Evotec has established a leading technology platform enabling the discovery, development and clinical translation of new cancer therapies. Evotec’s expertise includes the evaluation of small molecular weight compounds, natural compounds, biologics, cell therapies, gene therapies and vaccines.
With a team of ~150 scientists dedicated to oncology, Evotec has a significant background in a broad range of scientific areas, including tumour microenvironment, immuno-oncology, signal transduction, cancer metabolism, DNA damage and epigenetics.